Results 141 to 150 of about 113,669 (290)

Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa‐Therapy in Parkinson's Disease: A Randomized, Placebo‐Controlled Study (PREMANDYSK)

Movement Disorders, EarlyView.
Abstract Objective Investigate the efficacy of immediate‐release (IR) amantadine in reducing the risk of peak‐dose dyskinesia in early Parkinson's disease (PD) as add‐on to levodopa. Background While the use of amantadine to manage dyskinesia in PD is well supported by controlled clinical trials, data on its efficacy in patients without motor ...
Olivier Rascol, Fabienne Ory‐Magne, Wassilios G. Meissner, David Maltête, Luc Defebvre, Jean‐Philippe Azulay, Stéphane Thobois, Jean‐Luc Houeto, Claire Thalamas, Agnès Sommet, Christian Geny, Philippe Damier, Mathieu Anheim, Ana Marquès, François Viallet, Maurice Giroud, Romain Lefaucheur, Guillaume Costentin, Umberto Spampinato, Alexandra Samier‐Foubert, Nicolas Carrière, Eugénie Mutez, Louise‐Laure Mariani, Alexandre Eusebio, Stéphane Prange, Isabelle Benatru, Mahmoud Charif, Christine Brefel‐Courbon, Margherita Fabbri, Monique Galitzky, Vanessa Rousseau, Amandine Saubion, Hélène Catala, Joaquim J. Ferreira, David J. Burn, Jean‐Christophe Corvol, on behalf of the PREMANDYSK Study Group, Olivier Rascol, Fabienne Ory‐Magne, Claire Thalamas, Jean‐Christophe Corvol, Luc Defebvre, Wassilios G Meissner, David Maltête, Jean‐Philippe Azulay, Jean‐Luc Houeto, Stéphane Thobois, François Viallet, Alexandra Samier‐Foubert, Umberto Spampinato, Thomas Boraud, François Tison, Franck Durif, Ana Marques, Bérengère Debilly, Stéphane Bernard, Maurice Giroud, Nicolas Carrière, Eugénie Mutez, Frederic Torny, Philippe Couratier, Oliver Colin, Thomas Gaudin, Pierre Boutet, Emmanuel Broussolle, Stéphane Prange, Cathrine Caire, Hélène Merle, Alexandre Eusebio, Manel Nouira, Christian Geny, Mahmoud Charif, Philippe Damier, Pascal Derkinderen, Mirela Faighel, Violaine Talmant, Severine LeDily, Louise‐Laure Mariani, Lucette Lacomblez, Anne‐Marie Bonnet, Isabelle Benatru, Jean‐Luc Houeto, Solène Ansquer, Emilie Rabois, Anne Fradet, Romain Lefaucheur, Guillaume Costentin, Linda Vernon, Christine Tranchant, Matthieu Anheim, Ouhaid Lagha‐Boukbiza, Thomas Wirth, Agnès Sommet, Vanessa Rousseau, Hélène Catala, Monique Galiztky, Amandine Saubion, Christine Brefel‐Courbon, Margherita Fabbri, Nadéra Ainaoui, Estelle Dellapina, Alexandra Salis, Frédéric Eyvrard, Camille Jurado, Nicolas Boulloche, Jany Rey‐Zermati, Jean Jaques Boulesteix   +106 more
wiley   +1 more source

Benefits and risks of antipsychotic discontinuation in people with first and multi-episode psychotic disorders or with schizophrenia: why, when, how and in whom? [PDF]

Schizophrenia (Heidelb)
Correll CU, Rubio JM, Kane JM.
europepmc   +1 more source

Bipolar Disorder as a Long‐Term Risk Factor for Parkinson's Disease: A Nationwide Case–Control Study

Movement Disorders, EarlyView.
Abstract Background Previous studies suggest an association between bipolar disorder (BD) and an increased risk of Parkinson's disease (PD), but the long‐term temporal relationship remains unclear. Particularly, it is unclear whether the risk of PD is influenced by the duration since BD diagnosis.
Elina Jaakkola, Marjaana Koponen, Valtteri Kaasinen, Jarmo Hietala, Sirpa Hartikainen, Anna‐Maija Tolppanen   +5 more
wiley   +1 more source

Effectiveness of lifestyle interventions for preventing or managing the adverse cardiometabolic and other physical health effects of antipsychotic medications in children and adolescents: systematic review and meta-analysis. [PDF]

BJPsych Open
Hawker PJ, Bellamy J, Wong TY, McHugh C, Ward P, Wood A, Tonge B, Williams K, Bellgrove M, Silk TJ, Anderson V, Akram F, Eapen V.   +12 more
europepmc   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

Obesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu, Hao Dai, Huilin Tang, William T. Donahoo, Thomas J. George, Ramon C. Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D. Licht, John M. Allen, Kelvin P. Lee, Jingchuan Guo, Jiang Bian   +13 more
wiley   +1 more source

Real-World Adherence and Discontinuation of Oral Antipsychotics and Associated Factors in a National Sample of US Medicare Beneficiaries with Schizophrenia

ClinicoEconomics and Outcomes Research
Christopher Zacker,1 Justin T Puckett,2 Sachin Kamal-Bahl2 1Cerevel Therapeutics, LLC, Cambridge, MA, USA; 2COVIA Health Solutions, Ambler, PA, USACorrespondence: Sachin Kamal-Bahl, COVIA Health Solutions, 915 Brewster Lane Ambler, PA 19002, Tel +1 267 ...
Zacker C, Puckett JT, Kamal-Bahl S
doaj  

Special feature on antipsychotic discontinuation in schizophrenia. [PDF]

Schizophrenia (Heidelb)
Taylor D.
europepmc   +1 more source

Microwave‐Assisted Organic Syntheses in Deep Eutectic Solvents: A Win‐Win Association for Sustainable Chemistry

ChemistryOpen, EarlyView.
In organic synthesis, deep eutectic solvents (DES) have demonstrated their ability to be used as reaction media for the development of reactions in line with green chemistry principles. This review presents an overview of microwave‐assisted organic synthesis in DES, highlighting the diversity of uses for these solvents, their role in mechanisms, the ...
Pierre‐Olivier Delaye, Chefikou Salami, Emilie Thiery   +2 more
wiley   +1 more source

Helping people to discontinue antipsychotics: if, when and how. [PDF]

Schizophrenia (Heidelb)
Moncrieff J, Horowitz MA.
europepmc   +1 more source

Sexual dysfunction in patients taking conventional antipsychotic medication [PDF]

, 2002
Shubuladè Smith, Veronica O’Keane, Robin Murray   +2 more
openalex   +1 more source